What the 2025 TPE Clinical Trial Actually Proved, and What It Didn't

Does TPE work? Based on the best direct human evidence available, therapeutic plasma exchange appears to improve biological age biomarkers under controlled study conditions. In the May 2025 Aging Cell trial, TPE combined with IVIG reduced biological age by an average of 2.61 years, and TPE alone reduced it by 1.32 years. That matters. But the study did not prove longer lifespan, lower disease risk or guaranteed benefit for every patient. It measured biomarker change, not decades of clinical outcomes. Strong evidence, still early.

Disclosure: Liondale Medical is a Circulate Health partner, and Circulate collaborated with the Buck Institute on this trial. We tell you that up front so you can weigh our reading of the study accordingly. To see how the evidence translates into practice, start with therapeutic plasma exchange at Liondale Medical.

The Study: What Was Actually Done

If you are searching for the Buck Institute plasma exchange study or the 2025 TPE clinical trial, this is the paper people mean: Fuentealba et al., published in Aging Cell in May 2025. It was conducted by researchers affiliated with the Buck Institute for Research on Aging and Circulate Health. It enrolled 42 healthy adults over 50 and used a randomized, placebo-controlled design, which is a much higher bar than the average longevity headline.

Participants were assigned to treatment groups that included therapeutic plasma exchange alone, therapeutic plasma exchange with intravenous immunoglobulin, or control conditions. The investigators then tracked how those interventions changed a set of biological age biomarkers across multiple systems. The result that got the most attention was simple enough to repeat in one line: TPE plus IVIG produced an average biological age reduction of 2.61 years, and TPE alone produced an average reduction of 1.32 years.

What was measured was not wrinkles, VO2 max or who lived longer. The researchers used epigenetic clocks, which are DNA methylation-based biomarkers that estimate biological age, alongside broader multi-omics markers and physical measures. In practical terms, they asked whether the molecular pattern in a participant’s blood looked older or younger after treatment.

One detail keeps the conversation honest: only 2 of the 42 participants discontinued the study. So this was not magic, and it was not a frictionless wellness add-on. It was a real clinical protocol with measurable effects and measurable limits. For safety in more detail, read is TPE safe and who should consider it.

What Epigenetic Clocks Actually Measure

As we age, chemical tags called methyl groups accumulate and shift across specific sites on our DNA. Those patterns change in fairly predictable ways over time. Researchers examine thousands of sites at once and use them to generate a biological age estimate: not your birthday age, but the age your molecular profile resembles.

That is why clocks are widely used in aging research. They let scientists detect change on a biologically meaningful timescale without waiting 20 years to see who develops disease. But they are biomarkers, not final clinical outcomes. Saying your biological age markers improved is not the same as saying you will live longer. It is closer to saying your lab profile moved in a direction researchers associate with younger biology.

Biomarkers are not trivial just because they are not destiny. In cardiology, lipid markers matter, and in diabetes care, A1c matters. In aging science, epigenetic clocks have become a main tool for quantifying whether an intervention is moving biology in the desired direction. They are not a stand-alone clinical diagnostic, but they are worth taking seriously. If you want to see how we use them in practice, read how Liondale tracks TPE results.

What the Results Mean for Patients

The 2.61-year result is real under the conditions of the study. On average, participants who received TPE plus IVIG showed a measurable improvement in biological age biomarkers, and TPE alone also moved them, less dramatically. That is the signal.

The qualifier deserves equal airtime. It does not mean every person who gets TPE will shave 2.61 years off their biological age. That number is an average. Some participants likely responded more, some less and some may have shown little change. Good evidence narrows uncertainty without overpromising.

For patients, that means two things. TPE should be understood as a measured intervention, not a luxury add-on, and your own response should be tracked instead of assumed. If a clinic quotes the 2.61-year number but does not measure what happens in your case, it is borrowing the study’s credibility without doing the study’s work. For direct human longevity evidence, this trial is about as rigorous as the field currently gets, and for TPE it is the strongest controlled study to date.

If you want the practical version, compare it with our breakdown of TPE cost in NYC and our guide to TPE versus other longevity treatments. The point is not to push everyone into the same protocol. It is to show where the evidence is strongest, where it is thinner and who may actually be a fit.

The Earlier Evidence

The 2025 paper did not appear out of nowhere. A key earlier human paper was Kim et al. 2022 in GeroScience, titled Old plasma dilution reduces human biological age. It helped establish the biological rationale, namely that removing and replacing age-altered plasma can shift inflammatory and regenerative signaling in a younger direction. It examined changes in the systemic proteome, immune markers, DNA damage and senescence-related markers, and gave the field a plausible mechanistic backbone.

But it was a small, earlier-stage study with far less protection against bias than a randomized controlled design. The 2025 trial asked the next question: in a more rigorous structure, does the signal survive? The answer was yes. That progression, mechanism first and then more disciplined testing, is how good medicine is supposed to work. TPE now has both pieces. It is not perfect certainty, but it is a better evidence stack than most interventions sold under the longevity label.

What This Data Does NOT Prove

This is the section many clinics skip. We do not, because the caveats are where trust is earned or lost.

• It does not prove lifespan extension. A shift in biological age biomarkers is not proof you will live longer.
• It is one small trial. Forty-two participants is respectable for an early interventional study, but replication matters.
• The participants were healthy adults over 50. The results do not automatically apply to younger people or to people with significant medical conditions.
• The study team included researchers affiliated with Circulate Health. Independent replication would strengthen confidence.
• Epigenetic clocks are biomarkers, not clinical outcomes. They are not the same as heart attack rates, dementia incidence or all-cause mortality.
• It does not tell us what happens at 5 or 10 years. We do not know how durable the changes are or how they map onto major health outcomes.
• The 2.61-year reduction is an average. Individual response varies.

None of that weakens the study. It places it correctly. Good evidence should narrow uncertainty, not pretend to erase it. In longevity medicine the honest position is often: promising, measurable, not yet definitive.

Liondale’s response to that uncertainty is practical. We track individual biomarker response before and after treatment and adjust the protocol accordingly. If your markers move in the right direction, good. If they do not, we want to know early, not six months later after repeating a template plan.

How Liondale Uses This Evidence

Liondale is a Circulate Health partner. Circulate is the company that collaborated with the Buck Institute on the trial, and its work has been covered by outlets including the New York Times, Fortune, CNET, the Washington Post and Axios. In practice that means we use a Circulate-informed TPE model with pre- and post-treatment lab tracking and a patient-specific evaluation of whether IVIG belongs in the protocol. We do not claim to replicate the trial protocol or to promise its results.

Every session is treated as a measured intervention. We obtain pre- and post-treatment lab panels, review inflammatory and metabolic markers and, where appropriate, evaluate biological age biomarkers. Dr. Bissoon personally reviews the results and adjusts the plan. The protocol is standardized where it should be and individualized where it should be.

Many of our patients are already doing the basics well: sleep, exercise, nutrition and metabolic screening. They are not looking for hype. They want to know whether a treatment changes anything objective, and they want a physician willing to say when the answer is not yet clear. Read why patients choose Liondale for TPE in NYC or compare TPE providers in NYC to see how the model differs.

How to Read a Longevity Study Like a Skeptic

Headlines about aging research often skip the details that matter most. When you read about any longevity intervention, ask a few simple questions. Who was studied, and do they resemble you? What was measured, and is it a biomarker or a clinical outcome? How large was the study, and was there a comparison group? Was the result an average, and how much did individuals vary? Who conducted the work, and has anyone independent repeated it? Applying these questions to the 2025 TPE trial gives a balanced picture. The design was stronger than most, the participants were healthy adults over 50, the measure was biological age biomarkers, the group was small, and the researchers included people connected to the company that developed the protocol. None of that cancels the finding, but it shapes how much weight to give it. This kind of reading also protects you from clinics that quote a headline number without explaining what it means. A physician who welcomes these questions is usually one who measures your response instead of assuming it.

What Comes Next for TPE Research

The most useful next steps are larger trials, longer follow-up and independent replication. Researchers will want to know how long biomarker changes last, whether they translate into meaningful health outcomes, which patients respond best and how much treatment is truly necessary. Until those answers exist, the responsible approach is to treat TPE as a promising, measurable intervention and to track each patient’s response individually. We update our recommendations as the evidence develops.

Frequently Asked Questions

Does TPE really reverse biological age?

TPE has been shown to reduce biological age biomarkers in human studies, including an average 2.61-year reduction when combined with IVIG in the 2025 Aging Cell trial. That is not proof of longer lifespan or permanent age reversal, but it is legitimate evidence that measured biology moved in a younger direction.

What was the 2025 TPE clinical trial?

It was a randomized, placebo-controlled trial of 42 healthy adults over 50, published in Aging Cell in May 2025 by researchers affiliated with the Buck Institute for Research on Aging and Circulate Health. Participants received TPE alone, TPE with IVIG, or control conditions.

How reliable are epigenetic clocks as measurements?

They are among the most widely used biomarkers in aging research because DNA methylation patterns change predictably with age. They are useful for measuring response to an intervention, but they are not a stand-alone clinical diagnostic and should not be confused with disease events or survival.

How does the 2025 trial compare to earlier research?

The 2022 GeroScience paper established much of the biological rationale by showing that plasma dilution could shift age-related markers in a younger direction. The 2025 trial improved on it with a randomized, placebo-controlled design, making the result more persuasive.

Did everyone in the trial respond equally?

No. The 2.61-year and 1.32-year figures are averages, not guarantees. Individual response varied, and the study does not tell you how you personally would respond.

Was IVIG necessary for the effect?

TPE alone also moved biological age markers, by an average of 1.32 years, but the TPE plus IVIG arm was the most effective. IVIG carries separate risks and contraindications, so at Liondale it is evaluated patient by patient.

How many sessions were used in the trial?

The study included repeated treatment sessions. Protocols in practice are individualized, and there is no universally accepted schedule outside of trials.

What is the Buck Institute?

The Buck Institute for Research on Aging is a leading independent biomedical research institute focused on aging science. Its involvement gives the trial more scientific weight than a typical clinic case series or marketing claim.

Does Liondale use a Circulate-informed TPE protocol?

Yes. Liondale is a Circulate Health partner and uses a Circulate-informed TPE model with pre- and post-treatment lab tracking. IVIG is evaluated case by case, not applied by default.

What happens if my biomarkers don’t improve after treatment?

We do not assume success. We compare pre- and post-treatment labs and adjust the protocol based on the data. If markers do not move as expected, that becomes a clinical decision point, not something we ignore.

Is TPE proven to extend lifespan?

No. The trial measured biological age biomarkers, not lifespan, and long-term outcome data do not yet exist.

If you are weighing whether TPE fits your situation, schedule a consultation with Dr. Bissoon or read more about therapeutic plasma exchange at Liondale Medical.

Published May 18th, 2026